Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.92%
#2 Palladium Network Palladium Network +8.47%
#3 Cryptopia Cryptopia +4.23%
#4 Victoria VR Victoria VR +4.09%
#5 Lisk Lisk +3.02%
#6 Test Test +2.89%
#7 GRVT Token GRVT Token +2.39%
#8 Biconomy Biconomy +2.25%
#9 COTI COTI +2.22%
#10 Bless Bless +2.18%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Настройки
Язык
Pусский
Валюта
USD
Тема
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

SOBI
Ранг среди акций #1377
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in... Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Цена акции
$49.68
Рыночная капитализация
$17.25B
Изменение (1 день)
0.77%
Изменение (1 год)
72.50%
Страна
SE
Торговля Swedish Orphan Biovitrum AB (SOBI)

Категория

Healthcare
Количество находящихся в обращении акций Swedish Orphan Biovitrum AB (SOBI)
Количество акций в обращении на August 2026: 0
Согласно последним финансовым отчетам и цене акций Swedish Orphan Biovitrum AB, текущее количество акций в обращении составляет 0. На конец August 2026 у компании было 0 акций в обращении. Количество акций в обращении обычно зависит от сплитов и обратного выкупа акций.
История количества акций в обращении Swedish Orphan Biovitrum AB (SOBI) с 2026 по 2026
Акции в обращении на конец каждого года
Год Акции в обращении Изменить
Недостаточно данных для указанных дат.
Акции в обращении у аналогичных компаний или конкурентов
Компания Акции в обращении Разница Страна
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 445.06M -
US
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 105.38M -
US
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
 18.00B -
HK